On May 9, 2022 Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, reported that its Chief Medical Officer, Mark Berger, M.D., will be featured as an expert panelist at the 33rd Annual Cancer Progress Conference, taking place virtually May 10-12, 2022 (Press release, Genprex, MAY 9, 2022, View Source [SID1234613950]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The live panel discussion, titled, "Into the Unknown – Bringing New Modalities into Solid Tumors," will take place on Thursday, May 12 at 9 a.m. ET. This panel will explore considerations with respect to positioning of cell-based and other emerging immunotherapy platforms in solid tumors. Topics to be addressed by this panel include the current state of play, alignment of science with evolving unmet needs and perceived paths toward value inflection within different solid tumor markets.

Since 1989, Cancer Progress is the only oncology conference that facilitates discussions of scientific progress within the context of development, regulatory, clinical, commercial and investment perspectives over three days of provocative, informative panel discussions. The conference will feature pivotal topics, frank discussions, vigorous debate, opportunities for audience questions and comments, and a partnering platform to enable meaningful connections and meetings with innovators, developers and investors.